Loading...

Table of Content

    25 September 2024, Volume 29 Issue 05 Previous Issue    Next Issue
    For Selected: Toggle Thumbnails
    Experts forum
    Controversies and future directions of endoscope in breast surgery
    CAO Xuchen
    2024, 29 (05):  371-375.  DOI: 10.16139/j.1007-9610.2024.05.01
    Abstract ( 188 )   HTML ( 2 )   PDF (878KB) ( 16 )  

    Laparoscopic surgery has been widely applied in various surgical fields, demonstrating its advantages in minimally invasive procedures. However, for breast surgery, which lacks natural cavities, there remain certain controversies and unresolved issues. This review summarized the background, development, challenges, and solutions regarding the endoscope in breast surgery, and discussed the theoretical and practical basis for its application. Endoscope will become a new iterative tool in the field of breast surgery and is expected to provide a safer and minimally invasive way to serve more patients.

    References | Related Articles | Metrics
    Robotic-assisted surgical systems in treatment of breast cancer: applications and prospects
    ZHAO Xin, GAO Peng, CHEN Jie
    2024, 29 (05):  376-381.  DOI: 10.16139/j.1007-9610.2024.05.02
    Abstract ( 240 )   HTML ( 4 )   PDF (876KB) ( 81 )  

    In recent years, minimally invasive surgical techniques represented by endoscopic techniques and robotic surgical systems have become a new trend in the development of surgical treatment. With the advantages of precision, minimally invasive and aesthetics, robotic surgery has been more and more widely used in the field of breast surgery. By analysing literature, this paper reviewed the application of robotic surgery in breast cancer treatment in recent years, including the development of the technology, feasibility and safety of the surgery, etc., so as to provide a theoretical basis for the application of robotic surgical systems in breast cancer treatment.

    Figures and Tables | References | Related Articles | Metrics
    Suitable breast cancer screening strategy for Chinese women
    CAO Xi, LUO Yongchao, SHEN Songjie
    2024, 29 (05):  382-388.  DOI: 10.16139/j.1007-9610.2024.05.03
    Abstract ( 180 )   HTML ( 1 )   PDF (992KB) ( 14 )  

    Breast cancer poses a significant threat to the health and lives of Chinese women. Breast cancer screening can significantly improve the detection rate and breast conserving rate of early breast cancer, thereby enhancing patients’ quality of life and reducing mortality. Through analyses of the characteristics of breast cancer in Chinese women and related evidence-based medicine pertaining to screening, we suggested that the current breast cancer screening strategy for Chinese women should prioritize the strengthening of public health education to enhance cancer awareness and actively promote breast self-examination (BSE) and clinical breast examination (CBE). Breast imaging examination should mainly choose breast ultrasound, supplemented by mammography and breast magnetic resonance imaging. Risk stratification for breast cancer should be performed in the female population. For women at average risk, annual breast cancer screening should commence at age 40. For high-risk individuals, screening should be initiated earlier and at a higher frequency. With the changing of the epidemiological characteristics of breast cancer among Chinese women and the accumulation of new evidence, the suitable screening strategy for breast cancer in Chinese women also needs to be updated regularly.

    References | Related Articles | Metrics
    Application and research prospects of artificial intelligence in breast cancer pathological diagnosis
    DA Qian, RUAN Miao, FEI Xiaochun, WANG Chaofu
    2024, 29 (05):  389-395.  DOI: 10.16139/j.1007-9610.2024.05.04
    Abstract ( 424 )   HTML ( 43 )   PDF (1217KB) ( 690 )  

    Breast cancer is one of the most common cancers affecting women globally. With the advent of digital pathology slide scanners and the continuous evolution of deep learning algorithms, there has been a significant advancement in the application of artificial intelligence (AI) in the diagnosis and treatment of breast cancer. This article provided an overview of the current research and application status of AI in breast cancer pathological diagnosis, and summarized the challenges encountered as well as future directions in this field.

    Figures and Tables | References | Related Articles | Metrics
    Organ preservation strategies for rectal cancer treatment: tarts or trap?
    ZHOU Yihang, ZENG Ziwei, KANG Liang
    2024, 29 (05):  396-400.  DOI: 10.16139/j.1007-9610.2024.05.05
    Abstract ( 125 )   HTML ( 4 )   PDF (931KB) ( 16 )  

    Total mesorectal excision (TME) is the standard treatment for advanced mid- and low-rectal cancer. However, the associated surgical complications and subsequent impairment of organ function limit its application. In recent years, with advancements in neoadjuvant chemoradiotherapy and the implementation of immunotherapy, the pathological complete response (pCR) rate following neoadjuvant therapy for rectal cancer has significantly increased. This has raised questions about the necessity of performing TME in patients who achieve pCR. So as to, the clinical exploration of organ preservation strategies without radical surgery has been used in clinic. Current limited studies indicated that approaches such as watch & wait (W&W) or local excision have shown promising results in terms of long-term survival, and reduced surgical complications and functional impairment in some patients. However, challenges remain, including the difficulty in accurately assessing clinical complete response and the high rate of local recurrence, which could potentially compromise long-term survival. Further research into organ preservation strategies is needed, and careful consideration should be given to individual cases to prevent these strategies from becoming more of a “trap” than a “tart”.

    References | Related Articles | Metrics
    Consensus and guideline
    Hereditary breast cancer risk gene assessment and counseling: interpretation of NCCN guidelines and Ruijin Hospital clinical practice
    HAN Mengyuan, CHEN Xiaosong
    2024, 29 (05):  401-404.  DOI: 10.16139/j.1007-9610.2024.05.06
    Abstract ( 232 )   HTML ( 4 )   PDF (918KB) ( 26 )  

    Hereditary breast cancer-related gene mutations significantly increase the risk of breast cancer in women. In this regard, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Genetic/Familial High-Risk Assessment was developed to guide genetic assessment and counseling in mutation carriers of breast cancer risk genes, providing crucial information for the prevention, screening and treatment of breast cancer. This article provided an interpretation of the NCCN Clinical Practice Guidelines in Genetic/Familial High-Risk Assessment, integrating the clinical practice experience of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

    Figures and Tables | References | Related Articles | Metrics
    The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
    LU Yujie, ZHU Siji
    2024, 29 (05):  405-408.  DOI: 10.16139/j.1007-9610.2024.05.07
    Abstract ( 191 )   HTML ( 1 )   PDF (946KB) ( 55 )  

    Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.

    References | Related Articles | Metrics
    Original article
    Analysis of risk factors for non-sentinel lymph node metastasis in patients with sentinel lymph node-negative breast cancer
    ZHANG Fengzhe, TONG Yiwei, CHEN Xiaosong, SHEN Kunwei
    2024, 29 (05):  409-413.  DOI: 10.16139/j.1007-9610.2024.05.08
    Abstract ( 178 )   HTML ( 11 )   PDF (892KB) ( 19 )  

    Objective To analyze the risk factors for non-sentinel lymph node (NSLN) metastasis in patients with sentinel lymph node (SLN)-negative breast cancer. Methods Patients with breast cancer who underwent mastectomy and SLN biopsy at our center between January 2009 and August 2024 were retrospectively included. Univariate and multivariate analyses were performed in SLN-negative populations underwent low axillary lymph node dissection to identify risk factors for NSLN metastasis. Results A total of 2 387 SLN-negative patients were included, including 2 288 (95.9%) without NSLN metastasis and 99 (4.1%) with NSLN metastasis. Univariate and multivariate analyses showed that lymphovascular invasion (LVI) was an independent risk factor for NSLN metastasis in SLN-negative patients (13.5% versus 3.5%; OR=4.14,95% CI: 2.27-7.56,P<0.001). Patients with multicentric breast cancer showed a trend towards higher risk of NSLN metastasis compared to other types of breast cancer (9.5% versus 4.1%; OR=2.08,95% CI: 0.90-4.81,P=0.089). Conclusions Patients with SLN-negative biopsy who have LVI or multicentric breast cancer are at higher risk for NSLN metastasis.

    Figures and Tables | References | Related Articles | Metrics
    Expression and clinical significance of disulfidptosis-related LncRNA in gastric cancer
    CHU Yudan, SUN Haidong, CUI Ran, ZHENG Hong
    2024, 29 (05):  414-425.  DOI: 10.16139/j.1007-9610.2024.05.09
    Abstract ( 115 )   HTML ( 2 )   PDF (2646KB) ( 38 )  

    Objective To construct prognostic model of disulfidptosis-related LncRNA (DRLncs) and explore the mechanism of LncRNA-small nucleolar RNA host genes(SNHG4) in promoting the progression of gastric cancer. Methods The multi-omics features of disulfidptosis genes in gastric cancer were first analyzed based on The Cancer Genome Atlas(TCGA) database. DRLncs were further screened, and disulfidptosis related gene recurrence score (DRG-RS) model was constructed to predict the overall survival(OS) and correlation with the clinical characteristics of gastric cancer patients. Differential gene analysis, functional enrichment and the correlation between chemotherapy efficacy in high- and low-risk groups were analyzed. Cell-counting kit-8 (CCK-8) assay and migration assay confirmed that LncRNA-SNHG4 promoted the malignant phenotype of gastric cancer cells. Western Blotting assay was used to detect the signaling pathway regulated by LncRNA-SNHG4. Results DRG-RS model including 8 DRLncs was successfully constructed, showing good performance in predicting OS of the patients with gastric cancer. DRG-RS model was significantly correlated with tumor-related signaling pathways, clinical characteristics and drug sensitivity of gastric cancer patients. LncRNA-SNHG4 expression was significantly increased in gastric cancer. LncRNA-SNHG4 promoted the proliferation and migration of gastric cancer cells. LncRNA-SNHG4 promoted the activation of Wnt signaling pathway in gastric cancer cells. Conclusions The DRG-RS model constructed in our study can stratify the prognosis of gastric cancer, and is closely related to malignant characteristics and chemotherapy efficacy of gastric cancer patients. The expression of LncRNA-SNHG4 significantly increased in gastric cancer tissues, and LncRNA-SNHG4 promoted the malignant phenotype of gastric cancer cells through the Wnt signaling pathway, suggesting that LncRNA-SNHG4 may play an important role in the progression of gastric cancer.

    Figures and Tables | References | Related Articles | Metrics
    Anatomical simulation analysis of pancreaticobiliary junction in occult pancreaticobiliary reflux: based on Fluent study
    LÜ Beining, HOU Nianzong, XIANG Yukai, DA Xuanbo, YANG Yulong, TIAN Fuzhou
    2024, 29 (05):  426-433.  DOI: 10.16139/j.1007-9610.2024.05.10
    Abstract ( 142 )   HTML ( 1 )   PDF (3927KB) ( 56 )  

    Objective Computational fluid dynamics software combined with finite element method was used to conduct 2D numerical simulation of pancreaticobiliary junction, and analyze the influence of biliopancreatic ampullary diaphragm, opening direction and shape of duodenal papilla on occult pancreaticobiliary reflux(OPBR). Methods The data of anatomical structure of pancreaticobiliary junction were obtained from online information. Pancreaticobiliary junction was reconstructed in 2D by computational fluid dynamics Fluent 2020R2 software. Different models were drawn for the pancreaticobiliary junction according to the following parameters: biliopancreatic ampullary diaphragm (with/without), opening direction of duodenal papilla(biased to the side of bile duct/central/biased to the side of pancreatic duct). A total of 6 models were used to analyze the risk factors for OPBR. Results When the anatomical structure of the biliopancreatic duct confluence was normal, that was, the ampullary diaphragm exists, no matter how the shape of the duodenal papilla and the opening direction changed, there was no pancreaticobiliary reflux. When the common channel was >5 mm due to the absence of the ampullary diaphragm and duodenal papilla was biased to the side of bile duct, a small amount of pancreatic juice refluxed into the lower end of the bile duct. When the common channel was >5 mm due to the absence of the ampullary diaphragm and duodenal papilla open position was in the middle of the biliopancreatic duct, the velocity and flow rate of pancreatic juice entering bile duct increased, and the degree of reflux was maintained at the lower end of the bile duct. When the common channel was >5 mm due to the absence of the ampullary diaphragm and the duodenal papilla was biased to the side of pancreatic duct, the degree of pancreaticobiliary reflux was more serious, and pancreatic juice reflux was observed throughout the entire bile duct. On the basis of this reflux model, the length of common channel of biliopancreatic duct was shortened, and the opening of outflow tract was enlarged, and the phenomenon of pancreaticobiliary reflux disappeared. Conclusions Based on the Fluent study, it is found that anatomical structures such as ampullary diaphragm and duodenal papilla were closely related to the occurrence of OPBR. Pancreaticobiliary reflux can be terminated by shortening the common channel length of pancreaticobiliary junction and expanding the opening of outflow tract.

    Figures and Tables | References | Related Articles | Metrics
    Comparative efficacy of precut over a pancreatic duct stent and transpancreatic precut sphincterotomy for difficult biliary cannulation in ERCP
    YAO Wenfei, QI Yang, LI Qianyi, WU Yuquan, XU Ruiyun, YAO Wei, KONG Lei, LI Nengping
    2024, 29 (05):  434-440.  DOI: 10.16139/j.1007-9610.2024.05.11
    Abstract ( 150 )   HTML ( 2 )   PDF (11008KB) ( 17 )  

    Objective To compare the efficacy of precut over a pancreatic duct stent (PPDS) and transpancreatic precut sphincterotomy (TPS) for difficult biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP). Methods A retrospective analysis was conducted on the clinical data of all consecutive patients underwent ERCP by the same doctor in our hospital between April 2019 and March 2023. According to the selected method during difficult biliary cannulation when guidewire entered pancreatic duct unintendedly, the patients were divided into two groups,1) PPDS group: placing a pancreatic duct stent first, then using a needle knife to cut bile duct sphincter on the surface of the pancreatic duct stent, preserving pancreatic duct sphincter, and then selectively cannulate bile duct; 2) TPS group: precut through pancreatic duct sphincter first, then a pancreatic duct stent was placed, and bile duct was selectively cannulated. The success rate of biliary cannulation and ERCP-related complication between the two groups were compared. Results Among 762 ERCP patients, 84 patients were enrolled in this study, 44 patients in PPDS group, and 40 patients in TPS group. In PPDS group, 42 patients (95.4%, 42/44) had successful biliary cannulation. No post-ERCP pancreatitis(PEP), bleeding, perforation occurred in PPDS group. In TPS group, 39 patients (97.5%, 39/40) had successful biliary cannulation. Four patients (10.0%, 4/40) had PEP in PPDS group, no bleeding or perforation occurred. All patients were cured. The success rate of biliary cannulation between two groups had no significant difference(P>0.05), while the rate of PEP had significant difference(P<0.05). Conclusions Both PPDS and TPS are good choice for difficult biliary cannulation with high success rate of biliary cannulation. PPDS is more suitable for patients with high-risk factors for PEP, while TPS is a simple technique.

    Figures and Tables | References | Related Articles | Metrics
    Value of contrast-enhanced ultrasound in diagnosis of thrombus in inferior vena cava filter
    ZHANG Jian, QIAN Weiqing, YI Xiaolei
    2024, 29 (05):  441-445.  DOI: 10.16139/j.1007-9610.2024.05.12
    Abstract ( 136 )   HTML ( 2 )   PDF (4136KB) ( 11 )  

    Objective To evaluate the diagnostic value of contrast-enhanced ultrasound (CEUS) in assessing thrombus of inferior vena cava filters before filters removal. Methods We analyzed 127 patients who scheduled for inferior vena cava filter extraction from June to November 2023, 53 of which underwent CEUS examination. The enhancement of contrast agent signal within and around the filter was observed under CEUS mode. The thrombus was classified based on the signal loss of contrast agent and then compared with digital subtraction angiography(DSA). Results In the CEUS mode, the contrast agent was visualized within the inferior vena cava, clearly revealing signal loss for the thrombus location. Based on the size and location of the thrombus, filter thrombus was categorized into four groups: 41 cases of type 0, 8 cases of type Ⅰ, 3 cases of type Ⅱ, and 1 case of type Ⅲ. No significant difference in thrombus classification was observed between CEUS and DSA (P>0.05). According to the classification of filter thrombus, different extraction schemes were applied to 53 patients with inferior vena cava filters. There were no major bleeding events or symptomatic pulmonary embolism happened. Conclusions CEUS is valuable for evaluating filter thrombus prior to removal, providing a basis for preoperative assessment of surgical risks, selection of treatment plans, and prevention of complications.

    Figures and Tables | References | Related Articles | Metrics
    Clinical observation on the efficacy of non-lactating mastitis treated with staged surgery
    QU Wenchao, WAN Hua, WU Xueqing, FENG Jiamei, XIE Lu, GAO Qingqian, SHAO Shijun, SUN Jiaye
    2024, 29 (05):  446-451.  DOI: 10.16139/j.1007-9610.2024.05.13
    Abstract ( 144 )   HTML ( 1 )   PDF (1074KB) ( 7 )  

    Objective To explore the clinical efficacy of staged surgery for non-lactating mastitis. Methods A retrospective analysis was conducted on 317 patients with non-lactating mastitis admitted to our department from January 2015 to December 2020, all of whom underwent staged surgical treatment. The recovery time, recurrence rate, and breast appearance score were observed. Results The median follow-up time was 24(17,33) months, the recovery time was (25.5±17.9) days, and the recurrence rate was 4.4%. There were 96.2% of patients satisfied with the breast appearance. Conclusions Staged surgery for non-lactating mastitis can effectively shorten the course of the disease, protect the appearance of breast, and have good clinical efficacy.

    Figures and Tables | References | Related Articles | Metrics
    Case report
    Liver perforation caused by modified biliary stent of nasobiliary duct:a case report
    JIAO Yuanjun, YIN Yaoxin, LI Guixian, LIU Jikui, LIN Zewei
    2024, 29 (05):  452-454.  DOI: 10.16139/j.1007-9610.2024.05.14
    Abstract ( 131 )   HTML ( 1 )   PDF (1859KB) ( 27 )  

    There are many cases of biliary stent migration. Generally, biliary stent migrates distally. While, biliary stent rarely migrates proximally. Here we reported the case of a 49-year-old woman who underwent robot assisted right hemihepatectomy, and placement of a biliary stent for complicating bile leakage. The patient was discharged from hospital after recovering from bile leakage. Five months later, a follow-up examination revealed that the biliary stent had shifted into the liver, leading to liver perforation. We fully removed the stent by using a stone retrieval balloon and a snare. We suggested that when useing a biliary stent, it is necessary to consider of appropriate length of the stent and inform the patient when to return to the hospital for stent removal, in order to avoid stent migration and complications occurrence.

    Figures and Tables | References | Related Articles | Metrics
    Review
    Proceedings of clinical trials on bile tract cancer
    XIONG Yichen, YANG Ziyi, SANG Yuer, GONG Wei
    2024, 29 (05):  455-460.  DOI: 10.16139/j.1007-9610.2024.05.15
    Abstract ( 186 )   HTML ( 2 )   PDF (917KB) ( 15 )  

    Bile tract cancer (BTC) is aggressive and difficult to diagnose at an early stage. So far, radical surgery is the main curative measure for BTC, most patients with BTC are already in progressive or advanced stage at the time of diagnosis. Even after radical surgical resection, the risk of tumor recurrence remains high, and the 5-year survival rate is low. The results of several large-scale multicenter prospective clinical trials about BTC were published. All of these are significant for optimizing therapeutic strategies for BTC. BILCAP and ASCOT studies confirm the vital role of adjuvant chemotherapy in resectable BTC. Irinotecan as a second-line chemotherapy agent for patients with advanced BTC has also been confirmed by recent research data. TOPAZ-1 study was the first to demonstrate the superior efficacy of first-line immunotherapy combined with chemotherapy. In terms of targeted therapy, breakthroughs have been made in the development of HER2-targeting drugs such as zanidatamab, T-DXd, and neratinib. SAGC and SPINE studies showed that immunotherapy combined with chemotherapy or other targeted therapeutics may yield better survival benefit. Based on the data from these clinical studies, the corresponding guidelines have been updated both domestically and internationally. Along with the advances of tumor molecular diagnostic technology and the in-depth mining of gene expression information of BTC, BTC precision medical research has entered a new era. We expect more clinical studies and real-world data analysises and more clinical practice application experiences to provide better treatment options for BTC patients.

    References | Related Articles | Metrics